← Back to Clinical Trials
Recruiting NCT05572671

NCT05572671 Linking Brain Network Dynamics to Imminent Smoking Lapse Risk and Behavior

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05572671
Status Recruiting
Phase
Sponsor Penn State University
Condition Smoking
Study Type INTERVENTIONAL
Enrollment 150 participants
Start Date 2023-04-04
Primary Completion 2027-07

Trial Parameters

Condition Smoking
Sponsor Penn State University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 150
Sex ALL
Min Age 21 Years
Max Age 65 Years
Start Date 2023-04-04
Completion 2027-07
Interventions
Laboratory task modeling smoking lapse behavior

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Most attempts to quit smoking end in relapse, or a return to regular smoking. One of the biggest threats to cessation is a lapse (i.e., any cigarette use during a quit attempt). Thus, characterizing why lapses occur is essential to understanding and preventing smoking relapse. Functional magnetic resonance imaging (fMRI) is a promising method for characterizing the psychological processes that lead to smoking lapses because it provides a way to measures patterns of brain activity thought to reflect relevant mental processes as they change over time. However, methodological issues have hindered the ability to capitalize on this potential and prevented an understanding of how brain activity and corresponding psychological processes unfold in the critical moments that immediately precede a smoking lapse. The proposed project will address this knowledge gap using a novel fMRI paradigm adapted from a well-validated behavioral lapse task. The goals of the project are to characterize changes in brain activity that lead up to a lapse and to investigate how these changes are related to concurrent affect and subsequent cigarette use.

Eligibility Criteria

Inclusion Criteria: * Participants must be between the ages of 21 and 65. * Participants must be fluent English speakers. * Participants must pass an MRI safety screening. * Participants must report smoking at least six cigarettes per day continuously for at least the 12 preceding months. * Participants must have a baseline expired-air carbon monoxide exceeding 10 parts per million in order to verify smoking status. Exclusion Criteria: * Individuals will be excluded if they report that they are not willing to refrain from using nicotine for 12 hours before the experimental lab visit. * Individuals will be excluded if they have any known risk from exposure to high-field strength magnetic fields (e.g., pacemakers), any irremovable metallic foreign objects in their body (e.g., braces), or a questionable history of metallic fragments that are likely to create artifact on the MRI scans.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology